Ammonia and the Muscle: An Emerging Point of View on Hepatic Encephalopathy.

J Clin Med

Department of Translational and Precision Medicine, Centre for the Diagnosis and Treatment of Portal Hypertension, "Sapienza" University of Rome, 00185 Rome, Italy.

Published: January 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In the last years the link between the presence of muscular alterations and hepatic encephalopathy (HE), both minimal and overt, has been deeply studied. The pathophysiological background supporting the relationship between muscle depletion, and HE is characterized by an imbalance between the capacity of muscle in ammonia metabolism and trafficking and the inability of the liver in removing ammonia through urea synthesis due to liver failure and/or the presence of porto-systemic shunts. This review will focus on the clinical burden, the physio pathological mechanisms understanding the liver muscle axis and principles of management of muscular alterations in cirrhosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836353PMC
http://dx.doi.org/10.3390/jcm11030611DOI Listing

Publication Analysis

Top Keywords

hepatic encephalopathy
8
muscular alterations
8
ammonia muscle
4
muscle emerging
4
emerging point
4
point view
4
view hepatic
4
encephalopathy years
4
years link
4
link presence
4

Similar Publications

Simple scoring model for predicting overt hepatic encephalopathy in geriatric cirrhosis: A multicenter retrospective cohort study.

Metab Brain Dis

September 2025

Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu, 1-1 Yanagido, 501-1194, Japan.

Identifying the risk of overt hepatic encephalopathy (OHE) in geriatric patients with cirrhosis remains challenging. This study aimed to investigate the independent factors for OHE development in geriatric cirrhosis and to establish a simple scoring model to identify individuals at risk for OHE. We conducted a retrospective review of geriatric patients with cirrhosis aged ≥ 80 years who were admitted between April 2006 and November 2022.

View Article and Find Full Text PDF

Introduction: Cirrhosis progresses from compensated to decompensated phases, often marked by portal hypertension and complications like ascites, variceal hemorrhage, and hepatic encephalopathy. The ammonia-to-urea (A-to-U) ratio, reflecting urea cycle efficiency, may offer superior diagnostic performance compared to plasma ammonia levels alone. This study compared the diagnostic accuracy of the A-to-U ratio and plasma ammonia levels for identifying portal hypertension.

View Article and Find Full Text PDF

Background: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes (MALO) do not capture the added risk of return to drinking (RTD). We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH.

View Article and Find Full Text PDF

Patent ductus venosus is a congenital portosystemic shunt that may cause progressive portal hypertension, hepatic encephalopathy, and focal nodular hyperplasia of the liver. Embolization of the Arantius' duct is the first choice of treatment in infants and children. However, it carries the risk of coil migration into the systemic circulation in adult patients with larger Arantius ducts.

View Article and Find Full Text PDF

Acute or chronic liver damage can result in Hepatic Encephalopathy (HE), a potentially fatal neuropsychiatric condition that leads to cerebral and neurological alterations. Dapagliflozin (DAPA), an orally active Sodium/Glucose cotransporter 2 inhibitor with long duration of action. The study aim was to evaluate the potential protective impact of DAPA against HE caused by Thioacetamide (TAA) in rats.

View Article and Find Full Text PDF